Cytokinetics (CYTK) announced its support of a three-year initiative led by the American Heart Association, AHA, to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy, HCM. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Appoints New Executive VP and CLO
- Cytokinetics price target raised to $87 from $82 at RBC Capital
- Cytokinetics price target raised to $90 from $80 at B. Riley
- Cytokinetics presents additional data from MAPLE-HCM
- Promising Potential of Cytokinetics’ Aficamten Drives Buy Rating Amid Anticipated U.S. Approval